Literature DB >> 27245819

[Consolidation radiotherapy in primary gastric diffuse large B‑cell lymphoma with post-chemotherapy complete remission].

Christina Jentsch1,2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27245819     DOI： 10.1007/s00066-016-0993-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  13 in total

1.  The limits of limited stage lymphoma.

Authors:  Thomas P Miller
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

2.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors:  Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  Christophe Bonnet; Georges Fillet; Nicolas Mounier; Gérard Ganem; Thierry Jo Molina; Catherine Thiéblemont; Christophe Fermé; Bruno Quesnel; Claude Martin; Christian Gisselbrecht; Hervé Tilly; Félix Reyes
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

4.  Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Authors:  Joachim Yahalom; Tim Illidge; Lena Specht; Richard T Hoppe; Ye-Xiong Li; Richard Tsang; Andrew Wirth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-05-01       Impact factor: 7.038

5.  Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Authors:  Richard Delarue; Hervé Tilly; Nicolas Mounier; Tony Petrella; Gilles Salles; Catherine Thieblemont; Serge Bologna; Hervé Ghesquières; Maya Hacini; Christophe Fruchart; Loïc Ysebaert; Christophe Fermé; Olivier Casasnovas; Achiel Van Hoof; Antoine Thyss; Alain Delmer; Olivier Fitoussi; Thierry Jo Molina; Corinne Haioun; André Bosly
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

6.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

7.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.

Authors:  Félix Reyes; Eric Lepage; Gérard Ganem; Thierry J Molina; Pauline Brice; Bertrand Coiffier; Pierre Morel; Christophe Ferme; Andre Bosly; Pierre Lederlin; Guy Laurent; Hervé Tilly
Journal:  N Engl J Med       Date:  2005-03-24       Impact factor: 91.245

8.  Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Authors:  David Cunningham; Eliza A Hawkes; Andrew Jack; Wendi Qian; Paul Smith; Paul Mouncey; Christopher Pocock; Kirit M Ardeshna; John A Radford; Andrew McMillan; John Davies; Deborah Turner; Anton Kruger; Peter Johnson; Joanna Gambell; David Linch
Journal:  Lancet       Date:  2013-04-22       Impact factor: 79.321

9.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

10.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

Authors:  Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.